Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 10/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.32 |
| ▸ | GSK3B | P49841 | 3/20 | 0.32 |
| ▸ | SRC | P12931 | 2/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 4/20 | 0.31 |
| ▸ | PPARG | P37231 | 4/20 | 0.31 |
| ▸ | PPARA | Q07869 | 4/20 | 0.31 |
| ▸ | RXRB | P28702 | 3/20 | 0.31 |
| ▸ | RXRG | P48443 | 3/20 | 0.30 |
| ▸ | PPARD | Q03181 | 2/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957184 | 0.82 | MEN1 (0.40) | MEN1KMT2AGAASMN1; SMN2AURKA | |
| SCHEMBL2713578 | 0.80 | MEN1 (0.40) | MEN1KMT2AGAASMN1; SMN2AURKA | |
| SCHEMBL2614934 | 0.80 | AURKB (0.48) | AURKAAURKBSRCNTRK1 | |
| SCHEMBL3324249 | 0.80 | MAPT (0.43) | MEN1KMT2AGAASMN1; SMN2AURKA | |
| SCHEMBL2614935 | 0.80 | AURKA (0.42) | AURKAAURKBSRCNTRK1 | |
| SCHEMBL13004231 | 0.79 | AURKA (0.36) | AURKAAURKBSRCNTRK1 | |
| SCHEMBL2614899 | 0.78 | AURKB (0.45) | AURKAAURKBSRCNTRK1 | |
| SCHEMBL2614900 | 0.78 | AURKA (0.42) | AURKAAURKBSRCNTRK1 | |
| SCHEMBL2117208 | 0.78 | AURKA (0.46) | AURKAAURKBSRCNTRK1 | |
| SCHEMBL61333 | 0.77 | KMT2A (0.53) | MEN1KMT2AGAASMN1; SMN2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130324725-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-12-05 | — | — | US | disclosed |
| US-8455507-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120095014-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095014-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095014-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2146982-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008128009-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095014-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | AURKC, AURKA, AURKB | MEN1 1554/4885KMT2A 773/4885GAA 1528/4885 |
| US-20130324725-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | AURKC, AURKA, AURKB | MEN1 1554/4885KMT2A 773/4885GAA 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.